Compare NTIC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | ACRV |
|---|---|---|
| Founded | 1970 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.9M | 67.2M |
| IPO Year | 1996 | 2022 |
| Metric | NTIC | ACRV |
|---|---|---|
| Price | $8.10 | $1.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 8.6K | ★ 415.4K |
| Earning Date | 04-09-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $84,234,474.00 | N/A |
| Revenue This Year | $12.49 | N/A |
| Revenue Next Year | $7.64 | $568.17 |
| P/E Ratio | $413.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.14 | $1.20 |
| 52 Week High | $10.03 | $3.56 |
| Indicator | NTIC | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 65.74 |
| Support Level | $7.85 | $1.62 |
| Resistance Level | $8.53 | $2.02 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 10.65 | 74.07 |
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.